A Phase II, multi-center, randomized, double-blind study of T-4288 in patients with community-acquired pneumonia
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
Price : $35 *
At a glance
- Drugs Solithromycin (Primary) ; Levofloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Toyama Chemical
- 25 May 2016 Status changed from recruiting to completed, according to a Cempra Pharmaceuticals media release.
- 25 May 2016 Results published in a Cempra Pharmaceuticals media release.
- 17 Sep 2014 New trial record